

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Minako HIJIKATA, et al.

SERIAL NO: NEW APPLICATION

FILED: HEREWITH

FOR: CARRIER FOR GENE DETECTION AND ITS USE FOR DETECTING VALIDITY OF INTERFERON THERAPY

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references were filed in prior application Serial No.: 09/813,031, now allowed, where required, as were either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Norman F. Oblon

Registration No. 24,618

James J. Kelly, Ph.D.

Registration No. 41,504

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 241227US0SRDDIV		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Minako HIJIKATA et al.			
				FILING DATE HEREWITH		GROUP	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,972,692	10/26/99	Koji HASHIMOTO et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AG	WO 94/02606	02/03/94	WIPO			
	AH	WO 90/14593	11/29/90	WIPO			
	AI	WO 95/28492	10/26/95	WIPO			
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AQ	Ronni et al., "The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene", Journal of Interferon and Cytokine Research, vol. 18, no. 9, 1998, pp. 773-781.					
	AP	Chang et al., "Molecular and functional analysis of the virus and interferon-inducible human MxA promoter" ARCH VIROL, vol. 117, 1991, pp. 1-15.					
	AQ	Martin et al., Homo sapiens (subclone H8 4 b9 from P135 H5 C8), 7 September 1994 (1994-09-07), "Sequencing of the Mx1 region of the human chromosome 21" Database accession no.					
	AR	Kimmerly et al., Homo sapiens chromosome 21, P1 clone LBL#8, 4 September 1998 (1998-09-04) "Sequencing of human chromosome 21",					
	AS	Bashkirov et al., M. musculus mRNA for 3'-5' exonuclease, 17 March 1997 (1997-03-17).					
	AT	Iwashita et al., "5'-flanking region of R-ras GTPase activating protein" , 4 July 199 (1999-07-04).					
	AU	Souteyrand et al., "Direct detection of the hybridization of synthetic homo-oligomer DNA sequence by field effect", J. Phys. Chem. B., vol. 101, 1997, pp. 2980-2985.					
	AV	Kikuchi et al., "The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C" EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 10, no. 101, October 1998 (1998-10), pp 859-863.					
	AW	Hijikata et al., "Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon", Intervirology, vol. 43, April 2000 (2000-04), pp. 124-127.					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 241227US0SRDDIV		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Minako HIJIKATA et al.			
				FILING DATE HEREWITH		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAA	Guido ANTONELLI, et al., "Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN- $\alpha$ Therapy", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, Vol. 19, 1999, pgs. 243-251.					
	AAB	Tapani RONNI, et al., "The Proximal Interferon-Stimulated Response Elements Are Essential for Interferon Responsiveness: A Promoter Analysis of the Antiviral MxA Gene", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, Vol. 18, 1998, pgs. 773-781.					
	AAC	K.C. CHANG, et al., "Molecular and functional analysis of the virus- and interferon-inducible human MxA promoter", ARCHIVES OF VIROLOGY, Vol. 117, 1991, pgs. 1-15.					
	AAD	Masson et al., "Pharmacokinetic Optimisation of Cancer Chemotherapy", Clinical Pharmacokinetics, (1997), Vol. 32 (4), pp. 324-343.					
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							